All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Perimenopause hormone therapy: are 'better options' real?

Dr. Omar Akhter

TikTok creator

1.4K viewsWatch on TikTok→

Quick answer

This video addresses the undertreatment of perimenopause with evidence-based hormone therapy, specifically FDA-approved estradiol and micronized progesterone, in favor of SSRIs and oral contraceptives. The clinical concern is real and supported by NAMS 2022 guidelines, but the framing overgeneralizes by presenting SSRIs and combined oral contraceptives as categorically inappropriate rather than situationally indicated. Patients seeking hormone therapy for perimenopausal symptoms should be evaluated individually, with treatment selection based on symptom profile, contraindications, and informed patient preference.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @dromarakhter actually say?

Dr. Akhter argued that primary care physicians and gynecologists are too quick to prescribe SSRIs and oral contraceptives to perimenopausal women instead of bioidentical hormones like micronized progesterone and estradiol. The core claim: "there are better options out there" and women "don't need to be resigned to an SSRI or to birth control."

The video describes a patient in her late 40s with fatigue, poor mood, and weight gain. Her PCP offered an SSRI; her gynecologist offered birth control. Dr. Akhter frames this as a systemic failure to use what she calls "true hormone replacement therapy." The framing is pointed, the frustration is real, and a lot of patients watching will recognize themselves in this story. That emotional resonance doesn't make every claim accurate, though.

Does the science back this up?

Partly. The evidence for hormone therapy in perimenopause is genuinely stronger than clinical practice currently reflects, but the picture is messier than this video lets on.

The 2022 Menopause Society (NAMS) position statement supports low-dose hormone therapy as an effective option for vasomotor symptoms, mood disturbance, and sleep disruption in perimenopausal women under 60 without contraindications. A 2023 Lancet review (Davis et al.) confirmed estradiol-based therapy outperforms placebo for mood symptoms in perimenopause specifically, not just postmenopause. Micronized progesterone (Prometrium, or its generics) has a better safety profile than synthetic progestins, particularly for breast tissue and cardiovascular outcomes, per Fournier et al. (2008, Breast Cancer Research and Treatment).

However, SSRIs are not useless here. Escitalopram and venlafaxine have Level I evidence for vasomotor symptom reduction in women who cannot or choose not to use hormones (Loprinzi et al., multiple trials). Calling them categorically wrong overstates the case.

What did they get wrong (or right)?

Credit where it is due: the underuse of hormone therapy in perimenopause is a real and documented problem. A 2022 survey in Menopause (Crandall et al.) found that fewer than 30% of eligible perimenopausal women were ever offered hormone therapy by their provider. The reflexive reach for SSRIs in women presenting with mood symptoms, without first evaluating hormonal status, is a legitimate clinical concern. Dr. Akhter is on solid ground criticizing that pattern.

Where this video stumbles is in the framing of SSRIs and birth control as simply wrong. Low-dose combined oral contraceptives are actually guideline-supported for perimenopausal symptom management and contraception, particularly in nonsmoking women under 50 (ACOG Practice Bulletin 2022). They are not the same as HRT, but they are not the wrong call in every case. Presenting this as a binary, where hormones are right and everything else is a failure, shortcuts a conversation that should be individualized.

The term "bioidentical" also deserves scrutiny. When referring to FDA-approved micronized progesterone and estradiol patches, the science is solid. When the word gets used to implicitly endorse compounded hormone preparations, the evidence base is far weaker. This video does not explicitly recommend compounded hormones, but the language of "true hormone replacement" and "bioidentical" can push patients in that direction.

What should you actually know?

Perimenopause is undermanaged, and Dr. Akhter is right that women deserve more than a default SSRI prescription handed over without a hormonal workup. FDA-approved estradiol patches and micronized progesterone are well-studied, have a favorable risk profile in healthy women under 60, and are first-line options per NAMS, the British Menopause Society, and the Endocrine Society.

But "better options" does not mean one-size-fits-all. SSRIs remain appropriate for women with contraindications to estrogen, history of hormone-sensitive cancers, or personal preference. Oral contraceptives have a legitimate role in perimenopausal symptom management when selected appropriately. The failure is not that these drugs exist; it is that providers are skipping the conversation about what each patient actually needs.

  • If you are in perimenopause and feel dismissed, you are not imagining it. Provider education gaps are real.
  • Ask specifically about estradiol and micronized progesterone. Those are FDA-approved drugs with decades of safety data.
  • Be cautious about compounded "bioidentical" hormone preparations. They are not equivalent to FDA-approved versions and lack the same safety and efficacy data.
  • SSRIs are not inherently wrong for perimenopausal mood symptoms, but they should not be the first and only conversation.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Perimenopause hormone therapy: are 'better options' real?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Perimenopause hormone therapy: are 'better options' real? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Claim verdict

The useful answer behind this video

Claim being checked

This video addresses the undertreatment of perimenopause with evidence-based hormone therapy, specifically FDA-approved estradiol and micronized progesterone, in favor of SSRIs and oral contraceptives.

FormBlends verdict

This video addresses the undertreatment of perimenopause with evidence-based hormone therapy, specifically FDA-approved estradiol and micronized progesterone, in favor of SSRIs and oral contraceptives. The clinical concern is real and supported by NAMS 2022 guidelines, but the framing overgeneralizes by presenting SSRIs and combined oral contraceptives as categorically inappropriate rather than situationally indicated. Patients seeking hormone therapy for perimenopausal symptoms should be evaluated individually, with treatment selection based on symptom profile, contraindications, and informed patient preference.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • This video addresses the undertreatment of perimenopause with evidence-based hormone therapy, specifically FDA-approved estradiol and micronized progesterone, in favor of SSRIs and oral contraceptives. The clinical concern is real and supported by NAMS 2022 guidelines, but the framing overgeneralizes by presenting SSRIs and combined oral contraceptives as categorically inappropriate rather than situationally indicated. Patients seeking hormone therapy for perimenopausal symptoms should be evaluated individually, with treatment selection based on symptom profile, contraindications, and informed patient preference.
  • NAMS 2022 guidelines support hormone therapy as a first-line option for perimenopausal vasomotor and mood symptoms in healthy women under 60, meaning this is not fringe medicine.
  • Fewer than 30% of eligible perimenopausal women were offered hormone therapy by their provider, per Crandall et al. (2022, Menopause), confirming the underprescription problem Dr. Akhter raises.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • NAMS 2022 guidelines support hormone therapy as a first-line option for perimenopausal vasomotor and mood symptoms in healthy women under 60, meaning this is not fringe medicine.
  • Fewer than 30% of eligible perimenopausal women were offered hormone therapy by their provider, per Crandall et al. (2022, Menopause), confirming the underprescription problem Dr. Akhter raises.
  • FDA-approved micronized progesterone carries a better breast and cardiovascular safety profile than synthetic progestins, per Fournier et al. (2008, Breast Cancer Research and Treatment).
  • SSRIs, specifically escitalopram and venlafaxine, have Level I evidence for reducing vasomotor symptoms and remain appropriate for women with contraindications to estrogen.
  • Low-dose combined oral contraceptives are guideline-supported for perimenopausal symptom management in nonsmoking women under 50 per ACOG 2022, making them a legitimate tool, not a failure of care.
  • Compounded 'bioidentical' hormones are not equivalent to FDA-approved estradiol and micronized progesterone. The evidence base for compounded preparations is substantially weaker, and the FDA has not verified their safety or efficacy.
  • Davis et al. (2023, Lancet) found estradiol-based therapy specifically outperforms placebo for mood symptoms in perimenopause, strengthening the case for hormonal evaluation before defaulting to antidepressants.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Omar Akhter · TikTok creator

1.4K views on this video

There are better options out there. #perimenopause #hrt #hormonereplacement #progesterone #estradiol

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by Dr. Omar Akhter, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.